Market reactionShares fell 12% on Nov 5.
Lucid Diagnostics sells EsoGuard, a lab-developed DNA test (not FDA-approved) run on esophageal cells collected with its FDA-cleared EsoCheck device, to find precancer in people with chronic acid reflux.
Lucid's case rests on scaling paid EsoGuard testing. Medicare receipts have begun at $1,938.01 per test through the Texas pathway; California billing still depends on a revised LCD. Concert client plans also provide coverage. Q2 revenue of $1.5 million lagged $14.3 million in operating expenses. Cash of $33.4 million at June 30, 2026 was supplemented by a $15.0 million convertible preferred financing, with dilution risk. Collection feasibility supports expansion, but sustained paid growth remains essential; CMS's final payment determination is expected in November.
Thesis checklist
2 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Test volume and revenue grow
Does Medicare reimbursement translate into sustained growth in EsoGuard testing, revenue and collections?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Medicare payments begin; Lucid must turn reimbursement into sustained revenue growth
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Liver and digestive diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.